Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
April 28 2022 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report first quarter 2022 financial results and provide a
corporate update on Thursday, May 5, 2022. Jounce Therapeutics'
management team will host a live conference call and webcast at
8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (866) 916-3380 (domestic) or (210)
874-7772 (international) and refer to conference ID 9072989. The
live webcast can be accessed under "Events & Presentations" in
the Investors and Media section of the company's website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has multiple development stage programs ongoing while
simultaneously advancing additional early-stage assets from its
robust discovery engine based on its Translational Science
Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2
(ILT4) receptor antagonist shown to reprogram immune-suppressive
tumor associated macrophages to an anti-tumor state in preclinical
studies. JTX-8064 is currently being investigated alone and in
combination with pimivalimab (formerly JTX-4014), Jounce’s internal
PD-1 inhibitor, in one monotherapy and seven combination
indication-specific expansion cohorts in the Phase 1/2 INNATE trial
and is currently enrolling patients with advanced solid tumors in
the Phase 2 portion of the study. Jounce’s most advanced product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS, and is currently being studied in the SELECT Phase
2 trial. Pimivalimab is a PD-1 inhibitor intended for combination
use in the INNATE and SELECT trials and with Jounce’s broader
pipeline. Additionally, Jounce exclusively licensed worldwide
rights to GS-1811 (formerly JTX-1811), a monoclonal antibody
targeting CCR8 and designed to selectively deplete T regulatory
cells in the tumor microenvironment, to Gilead Sciences, Inc. For
more information, please visit www.jouncetx.com.
Investor and Media Contacts:Eric LaubJounce
Therapeutics, Inc.+1-857-259-3853elaub@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024